INTRODUCTION {#SEC1}
============

A key step during initiation of protein synthesis in eukaryotic cells is formation of the ternary complex (TC) composed of the translation initiation factor 2 (eIF2), GTP and initiator Met-tRNA~i~^Met^. The eIF2 itself is a heterotrimer of distinct α, β and γ subunits. The eIF2 TC binds to the 40S small ribosomal subunit, along with other translation factors, forming a 43S preinitiation complex (PIC) that binds near the 5′ end of a messenger RNA (mRNA) forming a 48S PIC. The 48S PIC then scans down the mRNA ([@B1]). The translation start site, typically an AUG codon, is selected by base-pairing interactions between the anticodon of the tRNA~i~^Met^ and the mRNA. Start codon selection triggers completion of GTP hydrolysis by eIF2, release of P~i~ and subsequent release of eIF2--GDP ([@B1]). In addition to mediating delivery of Met-tRNA~i~^Met^ to the ribosome, eIF2 also plays a critical role in selection of the translation start codon. Mutations have been isolated in all three subunits of yeast eIF2 that relax the stringency of start site selection and promote initiation at a near cognate start codon ([@B4]). Recently, multiple cases of an X-linked intellectual disability (XLID) syndrome caused by mutations in the *EIF2S3* gene, encoding the eIF2γ subunit, have been identified ([@B9]). The acronym MEHMO denotes the characteristic symptoms of this syndrome: Mental deficiency, Epilepsy, Hypogenitalism, Microcephaly and Obesity ([@B13]). While severely affected patients exhibit all symptoms, less affected patients exhibit only a subset of the symptoms. Furthermore, it remains unknown why symptom severity is variable between patients and how each of the identified mutations impacts eIF2 function. Thus, there is a critical need to determine the underlying molecular mechanism governing the phenotype of the MEHMO patients.

Genetic analyses of MEHMO syndrome patients have identified several unique mutations in *EIF2S3* that map to distinct regions of eIF2γ ([@B9]), suggesting that the different mutations will likely impact distinct eIF2 functions. We previously characterized the MEHMO mutation I222T, located on the back face of the eIF2γ GTP-binding domain (Figure [1B](#F1){ref-type="fig"}). This eIF2γ-I222T mutation lies in a cleft that forms the docking site for helix α1 of eIF2β. Accordingly, the eIF2γ-I222T mutation impaired the interaction of overexpressed eIF2γ with the endogenous eIF2β in human cells ([@B9]). Likewise, mutation of the corresponding residue (V281) in yeast eIF2γ, encoded by the *GCD11* gene, impaired eIF2β binding. In addition to impairing eIF2β binding to eIF2γ, the V281T mutation in yeast eIF2γ caused modest derepression of *GCN4* expression, a sensitive reporter of eIF2 function in yeast, and impaired the stringency of translation start site selection in reporter gene experiments as revealed by increased initiation at a near cognate UUG codon. A second mutation linked to MEHMO syndrome, eIF2γ-I465Sfs\*4, is caused by a 4-nt deletion near the 3′ end of the eIF2γ open reading frame ([@B10]). The mutation introduces a frameshift and changes the C-terminal residues of eIF2γ. While the molecular defect associated with the I465Sfs\*4 mutation has not been resolved, the corresponding mutation in yeast eIF2 derepresses *GCN4* expression and decreases the stringency of translation start site selection ([@B12]). A third mutation in *EIF2S3* linked to MEHMO syndrome changed the poorly conserved S108 residue to arginine; however, it is unclear how this mutation impacts eIF2 function and the corresponding mutation in yeast eIF2γ had no phenotype. Consistent with the lack of phenotype in yeast, the S108R mutation was associated with milder symptoms in the patient.

![MEHMO syndrome mutation eIF2γ-I259M lies in the transfer RNA (tRNA)-binding pocket of eIF2γ and the corresponding yeast eIF2γ-I318M mutation confers a slow-growth phenotype. (**A**) Ribbons representation of *Sulfolobus solfataricus* aIF2--GDPNP--Met-tRNA~i~^Met^ TC (PDB code 3V11; ([@B25])) using PyMOL software (Schrodinger). Components are colored as follows: tRNA~i~^Met^, green; Met, purple, aIF2α, yellow; aIF2β helix α1, slate; GTP, gold and aIF2γ, cyan. (**B**) Magnification of the aIF2γ tRNA-binding pocket to highlight the proximity of *Ss*I218 (*Hs*I259, blue) to Met-tRNA~i~^Met^. Sites of three other mutations identified in patients with MEHMO syndrome are highlighted in stick representation including *Ss*I181 (*Hs*I222, red), *Ss*T69 (*Hs*S108, brown) and a C-terminal frameshift mutation (orange). (**C**) Magnification of aIF2γ from panel (B). MEHMO syndrome mutation site *Ss*I218 (*Sc*I318, *Hs*I259; blue) and the adjacent *Ss*R219 (*Sc*R319, *Hs*R260; pink) residues are highlighted. (**D**) Residues forming the methionine (magenta) binding pocket in *Saccharomyces cerevisiae* eIF2γ, taken from the structure of the yeast 48S PIC (PDB code 3JAP; ([@B42]). (**E**) Serial dilutions of yeast strains expressing the indicated WT or mutant forms of eIF2γ were spotted onto SD minimal medium containing essential amino acid supplements and plates were incubated at 30°C for 2 days. (**F**) Whole cell extracts (WCEs) from yeast strains expressing the indicated wild-type or mutant forms of eIF2γ were subjected to (SDS-PAGE) followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2γ or GCD6 (eIF2Bϵ).](gky1213fig1){#F1}

A fourth mutation in eIF2γ-I259M, was identified in two male siblings with severe microcephaly, growth retardation, seizures and intellectual disability ([@B10]), and thus likely also causes MEHMO syndrome. To gain insights into the molecular impact of the I259M mutation on eIF2 function, we mutated the corresponding residue (I318) in *S. cerevisiae* eIF2γ. Our studies revealed that the I318M mutation in yeast eIF2γ, like other MEHMO syndrome mutations in eIF2γ, leads to derepressed *GCN4* expression and relaxed stringency of translation start site selection *in vivo*. However, in contrast to the previously characterized MEHMO mutations in eIF2γ, the I318M impairs Met-tRNA~i~^Met^ binding to eIF2 both *in vivo* and *in vitro*. Thus, these studies provide insights into the structure-function properties of eIF2 and expand our understanding into the ways in which eIF2 function can be impaired to cause MEHMO syndrome.

MATERIALS AND METHODS {#SEC2}
=====================

Yeast strains and plasmids {#SEC2-1}
--------------------------

Yeast strain J292 (*MATα leu2-3,-112 ura3-52 his3 gcn2Δ::loxP gcd11Δ::KanMX* p\[*GCD11, URA3*\]) ([@B5]) was used for the analysis of eIF2γ mutants. Mutant alleles of *GCD11* were generated by site-directed mutagenesis and introduced into J292 as the sole source of eIF2γ by plasmid shuffling ([@B14]). Plasmids used in this study are listed in Table [1](#tbl1){ref-type="table"}.

###### 

Plasmids used in this study

  Plasmid   Description                                Reference
  --------- ------------------------------------------ ------------
  p180      *GCN4-lacZ, URA3, CEN4/ARS*                ([@B20])
  p367      *HIS4(AUG)-lacZ, URA3*                     ([@B30])
  p391      *HIS4(UUG)-lacZ, URA3*                     ([@B30])
  pC2872    His~8~-*GCD11* (eIF2γ), *LEU2, CEN4/ARS*   ([@B5])
  pC4188    His~8~-*gcd11-V281T* in pC2872             ([@B9])
  pC4187    His~8~-*gcd11-V281K* in pC2872             ([@B9])
  pC5856    His~8~-*gcd11-I318M* in pC2872             This study
  pC5857    His~8~-*gcd11-I318L* in pC2872             This study
  pRS423    *HIS3*, 2μ                                 ([@B48])
  pC1682    *SUI2* (eIF2α) in pRS423                   ([@B32])
  pC4191    *SUI3* (eIF2β) in pRS423                   ([@B9])
  pC1683    *IMT4* (tRNA~i~^Met^) in pRS423            ([@B32])
  WB759     *TK-ATF4-luc* in pGL3                      ([@B28])
  pC4293    pcDNA4/TO/myc-HisA                         ([@B9])
  pC4291    human eIF2γ in pcDNA4/TO/myc-HisA          ([@B9])
  pC6155    human eIF2γ-I259M in pC4291                This study

Growth analysis {#SEC2-2}
---------------

Derivatives of yeast strain J292 expressing WT or mutant forms of eIF2γ, either alone or with an empty vector (pRS423) or various high copy-number plasmids to overexpress eIF2α (pC1682), eIF2β (pC4191) or tRNA~i~^Met^ (pC1683), were grown to saturation in minimal SD medium with required amino acid supplements. Five microliter volumes of serial dilutions (OD~600~ = 1.0, 0.1, 0.01, 0.001 and 0.0001) were spotted onto SD medium containing required amino acid supplements, and the plates were incubated at 30°C for 3 days.

Western blot analysis {#SEC2-3}
---------------------

Yeast strains expressing WT or mutant forms of eIF2γ were grown to OD~600~∼1 in 100 ml SD medium containing required amino acid supplements at 30°C. Cells were harvested, washed with 5 ml Breaking Buffer A (20 mM Tris--HCl (pH 7.5), 500 mM KCl, 0.1 mM MgCl~2~, 5 mM β-mercaptoethanol, 10% (v/v) glycerol, 1× cOmplete protease inhibitor (Sigma-Aldrich) and 1 mM \[4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), Sigma\]), and resuspended in 1 ml Breaking Buffer A. Cells were lysed by adding 50% (w/v) glass beads and then vigorous mixing on a vortex for 5 min at 4°C. Lysates were cleared by centrifugation at 15 700 × *g* for 10 min at 4°C, quantified, mixed with sodium dodecyl sulphate (SDS)-sample buffer and incubated at 70°C for 10 min. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2γ ([@B15]), eIF2β ([@B16]), eIF2α ([@B17]) and GCD6 ([@B18]).

β-galactosidase assays {#SEC2-4}
----------------------

For measurement of *GCN4-lacZ, his4(UUG)-lacZ* or *HIS4(AUG)-lacZ* expression, yeast cultures were grown overnight to saturation in SC medium and then used to inoculate 25 ml of SC medium at OD~600~ = 0.25. Cultures were grown 6 h to OD~600~≤1 and β-galactosidase activities were determined as previously described ([@B19],[@B20]). Means and standard deviations of β-galactosidase activities were calculated for three independent transformants.

Cell culture and luciferase assays {#SEC2-5}
----------------------------------

HEK293T cells were obtained from American Type Culture Collection and maintained in Dulbecco Modified Eagle Medium (DMEM) containing 4.5 g/l D-glucose, L-glutamine and 110 mg/l sodium pyruvate (Gibco) that was supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 1% penicillin/streptomycin (Quality Biological). For measurements of *ATF4-luc* expression, *ATF4-luc* and a *Renilla* reporter plasmid were transiently co-transfected with an empty vector or overexpression plasmids encoding WT eIF2γ or eIF2γ-I259M into HEK293T cells following the Lipofectamine 3000 (Invitrogen) manufacturer's protocol. Culture media was exchanged for fresh DMEM medium 8 h after transfection. Cell lysis and measurement of relative luciferase activities were conducted following the Promega Dual-Luciferase Reporter Assay System protocol with a Centro XS LB 960 High Sensitivity Microplate Luminometer. Means and standard deviations of relative luciferase activities were calculated for three biological replicates.

eIF2 purification {#SEC2-6}
-----------------

Preparation of eIF2 was performed as previously described ([@B21]) with the following modifications. Yeast strains expressing WT eIF2γ or eIF2γ-I381M were grown to OD~600~∼4 in 10 l yeast extract peptone dextrose (YPD) medium at 30°C. Cells were pelleted by centrifugation at 6000 × *g* for 10 min at 4°C, and cell pellets were frozen at −80°C overnight. The following day, cells were lysed using a Waring Blender, 50% (w/v) glass beads, in 200 ml Lysis Buffer (75 mM Tris--HCl (pH 7.5), 100 mM KCl, 0.1 mM GDP, 14 mM β-mercaptoethanol and 1× cOmplete protease inhibitor (Roche)). Lysates were clarified by centrifugation at 15 000 × *g* for 30 min at 4°C. The supernatant was transferred to a beaker and ammonium sulfate was added gradually to 75% saturation over 1 h at 4°C. The slurry was then pelleted by centrifugation at 15 000 × *g* for 30 min at 4°C, and the pellet was resuspended in Buffer A (20 mM Tris--HCl (pH 7.5), 0.5 M KCl, 0.1 mM MgCl~2~, 20 mM imidazole, 10% (v/v) glycerol, 10 μM GDP, 5 mM β-mercaptoethanol and 1× cOmplete protease inhibitor). Following addition of 10 ml Ni-NTA resin (Qiagen), samples were stirred for 1 h at 4°C. The Ni-NTA resin was subsequently washed with 30 ml Buffer A, and eIF2 complexes were eluted in 20 ml Buffer B (20 mM Tris--HCl (pH 7.5), 0.5 M KCl, 0.1 mM MgCl~2~, 500 mM imidazole, 10% (v/v) glycerol, 10 μM GDP, 5 mM β-mercaptoethanol and 1× cOmplete protease inhibitor). The elute was dialyzed overnight against 0.5 l Dialysis Buffer (20 mM Tris--HCl (pH 7.5), 100 mM KCl, 0.1 mM MgCl~2~, 10% (v/v) glycerol, 10 μM GDP and 2 mM dithiothreitol (DTT)) at 4°C. Samples were then clarified by centrifugation at 4000 × *g* for 10 min at 4°C, and the supernatant was passed through a 0.45 μm filter to clear up the solution. Samples were loaded onto an equilibrated HiTrap Heparin column (Amersham) and further processed as described previously ([@B21]). Fractions containing eIF2 were identified by SDS-PAGE, pooled, dialyzed against Storage Buffer (20 mM Tris--HCl (pH 7.5), 100 mM KAc, 0.1 mM MgAc, 10% (v/v) glycerol and 2 mM DTT), aliquoted and stored at −80°C.

Synthesis and aminoacylation of tRNA~i~^Met^ {#SEC2-7}
--------------------------------------------

Yeast tRNA~i~^Met^ was synthesized by *in vitro* transcription with T7 polymerase as described previously ([@B21]). His-tagged MetRS was purified from *Escherichia coli* XL1 Blue cells (Agilent) carrying the *E. coli* methionyl-tRNA synthetase (MetRS) expression plasmid pRA101 ([@B22]) as described previously ([@B23]). Aminoacylation reactions with 5 μM synthesized tRNA~i~^Met^, 2 mM adenosine triphosphate-Mg^2+^, 0.3 μM \[^35^S\]methionine (Perkin Elmer), 10 mM MgCl~2~ and 1 μM MetRS were incubated in 1× Reaction Buffer (100 mM HEPES-KOH (pH 7.5), 1 mM DTT and 10 mM KCl) for 30 min at 30°C, and aminoacylated Met-tRNA~i~^Met^ was purified by phenol/chloroform extraction ([@B21]).

Met-tRNA~i~^Met^ and guanine nucleotide affinity measurements {#SEC2-8}
-------------------------------------------------------------

For measurements of tRNA binding, seven 2-fold serial dilutions of eIF2 with final concentrations from 3.125 to 200 nM were incubated for 15 min at 26°C in Binding Assay Buffer (25 mM HEPES-KOH (pH 7.6), 2.5 mM Mg(OAc)~2~, 80 mM KOAc (pH 7.6), 2 mM DTT and 0.5 mM guanosine 5′-\[β,γ-imido\]triphosphate (GDPNP)-Mg^2+^). \[^35^S\]Met-tRNA~i~^Met^ was added to a final concentration of 1 nM and reactions were incubated for 15 min at 26°C, followed by vacuum filtration as previously described ([@B21]). For measurements of GDP affinity, final concentrations from 3.125 to 200 nM eIF2 were incubated for 15 min at 26°C in Binding Assay Buffer lacking GDPNP-Mg^2+^. \[^3^H\]GDP was added to a final concentration of 2 nM and reactions were incubated for 15 min at 26°C followed by vacuum filtration as previously described ([@B24]). Means and standard deviations for the fraction of \[^35^S\]Met-tRNA~i~^Met^ or \[^3^H\]GDP bound to eIF2 were calculated for three independent experiments. Binding curves were fit using the program Kaleidagraph to the equation: fraction bound = *B*~max~\[S\] / (*K*~d~ + \[S\]), where *B*~max~ is the maximum fraction bound at excess substrate \[S\].

eIF2γ pull-down assay {#SEC2-9}
---------------------

Yeast strains expressing His-tagged forms of WT or mutant eIF2γ, either alone or with an empty vector (pRS423) or high copy-number *IMT4* (tRNA~i~^Met^) plasmid (pC1683), were grown to OD~600~ ∼ 1 in 200 ml SD medium with amino acid supplements at 30°C. Cells were harvested, washed with 10 ml Breaking Buffer B (20 mM Tris--HCl (pH 7.5), 500 mM KCl, 0.1 mM MgCl~2~, 10 mM imidazole, 5 mM β-mercaptoethanol, 10% (v/v) glycerol, 1× cOmplete protease inhibitor and 1 mM AEBSF), and resuspended in 2 ml Breaking Buffer B. Cells were lysed by adding 50% (w/v) glass beads and then vigorous mixing on a vortex for 5 min at 4°C. Lysates were cleared by centrifugation at 14 000 × *g* for 10 min at 4°C and divided into quarters. For protein input samples, one quarter of the lysate was quantified, mixed with SDS-sample buffer and incubated at 70°C for 10 min. For analysis of Met- tRNA~i~^Met^ in input samples, one quarter of the lysate was quantified and subjected to RNA isolation using TRIzol LS Reagent (Invitrogen), followed by reverse transcriptase-polymerase chain reaction (RT-PCR) as described below. For eIF2γ pull-down analysis, two quarters of the lysate were independently mixed with 0.1 ml Ni-NTA resin, incubated with slow rocking on a nutator for 2 h at 4°C and then washed three times with 5 ml Breaking Buffer B. Beads were then either mixed with SDS-sample buffer or with TRIzol LS Reagent. Input and pull-down protein samples were subjected to SDS-PAGE followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2γ, eIF2β and eIF2α.

For analysis of Met-tRNA~i~^Met^, RNA was extracted from the input and pull-down samples using TRIzol LS Reagent (Invitrogen) according to the manufacture's protocol. Reverse transcription (RT) was conducted using SuperScript III First-Strand Synthesis SuperMix (ThermoFisher Scientific) with random hexamers according to the manufacturer's protocol. For RT reactions, 2.5 μl RNA was utilized for input samples and all of the isolated RNA was utilized for pull-down samples. PCR reactions of input and pull-down samples were conducted using Phusion Hot Start II DNA Polymerase (ThermoFisher Scientific), 1× Phusion HF buffer, 200 μM deoxynucleotide triphosphates (dNTPs), 0.5 μM Forward Primer (5′-GCAGGGCTCATAACCCTGAT-3′), 0.5 μM Reverse Primer (5′-TAGCGCCGCTCGGTTTC-3′) and 1 μl RT products in 50 μl total volume. PCR was performed under the following conditions: (i) 98°C for 30 s; (ii) 15 cycles of 98°C for 10 s, 59°C for 30 s and 72°C for 2 s; and (iii) 72°C for 5 min. Reactions products were resolved by electrophoresis on a 2.5% agarose gel and stained with GelRed Nucleic Acid Stain (Biotium).

RESULTS {#SEC3}
=======

MEHMO syndrome mutation eIF2γ-I259M lies in the Met-tRNA~i~^Met^-binding pocket and the corresponding I318M mutation in yeast eIF2γ impairs cell growth {#SEC3-1}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Recent X-chromosome exome sequencing identified a missense mutation (I259M) in the *EIF2S3* gene encoding eIF2γ of two male siblings with MEHMO syndrome phenotypes, including severe microcephaly, growth retardation, seizures and intellectual disability ([@B10]). The I259 residue is located in domain II of eIF2γ and is conserved among archaeal aIF2γ and eukaryotic eIF2γ proteins, suggesting that the residue could be of functional importance. Both eIF2γ and the eIF2 complex are well conserved through evolution and structural studies on aIF2 and eIF2 complexes provide useful insights into the structure of human eIF2. High-resolution structures of the aIF2 TC, as well as of the yeast 48S PIC, reveal interactions among the eIF2α, eIF2β and eIF2γ subunits that mediate eIF2 heterotrimer formation as well as the interactions between Met-tRNA~i~^Met^ and the eIF2 heterotrimer.

Based on the crystal structure of the *Sulfolobus solfataricus* (*Ss* ) aIF2 TC, composed of aIF2α, aIF2β, aIF2γ, GTP and Met-tRNA~i~^Met^ (Figure [1A](#F1){ref-type="fig"}) ([@B25]), the Ile218 residue in aIF2γ, which is analogous to the Ile259 mutation site in *Homo sapiens* eIF2γ and I318 in *S. cerevisiae* eIF2γ, lies in the tRNA-binding pocket of aIF2γ (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). Intriguingly, I218 in aIF2 is only ∼7Å from the methionine residue on Met-tRNA~i~^Met^, and the adjacent residue R219 makes direct contacts with the Met residue (Figure [1C](#F1){ref-type="fig"}). The proximity of I218 to a contact point with Met-tRNA~i~^Met^ raises the possibility that the I259M mutation in the patients with MEHMO syndrome phenotypes might impair eIF2 TC formation by disrupting initiator Met-tRNA~i~^Met^ binding to the eIF2 complex.

As it is challenging to study eIF2 mutations in mammalian systems, in part, because it has not been possible to prepare recombinant forms of mammalian eIF2 for biochemical studies, we use *in vivo* assays in *S. cerevisiae* and complementary biochemical experiments with purified wild-type and mutant yeast factors to study the impact of mutations on eIF2 function. Growth analyses were conducted for yeast strains lacking the chromosomal *GCD11* gene encoding eIF2γ and expressing wild-type (WT) eIF2γ, eIF2γ-V281T, eIF2γ-V281K, eIF2γ-I318M or eIF2γ-I318L from a single copy-number plasmid. As shown previously ([@B9]) the V281T mutation, corresponding to the I222T mutation identified in a patient with MEHMO syndrome, had no impact on yeast cell growth compared to cells expressing WT eIF2γ (Figure [1E](#F1){ref-type="fig"}, rows 1 and 2); however, the Lys mutation at the same site (V281K) substantially impaired growth (Figure [1E](#F1){ref-type="fig"}, rows 1 and 3) consistent with its more severe impact on eIF2β binding to eIF2γ ([@B9]). The I318M mutation in yeast eIF2γ, corresponding to the I259M mutation in the patient, also resulted in a marked slow-growth phenotype (Figure [1E](#F1){ref-type="fig"}, row 4). In contrast, the I318L mutation did not impact yeast cell growth (Figure [1E](#F1){ref-type="fig"}, row 5). Western analyses revealed similar levels of eIF2γ in the strains, indicating that the growth defect in the strain expressing eIF2γ-I318M is due to impaired eIF2γ function and not to altered eIF2γ levels (Figure [1F](#F1){ref-type="fig"}).

The eIF2γ-I318M mutation derepresses *GCN4* reporter expression and reduces start codon selection stringency {#SEC3-2}
------------------------------------------------------------------------------------------------------------

To further explore how the I318M mutation disrupts eIF2γ function, we examined translational control of a *GCN4* reporter in the yeast strains expressing WT or mutant forms of eIF2γ. GCN4 is a transcriptional activator whose synthesis is governed by regulated translation reinitiation at upstream open reading frames (uORFs) in the leader of the mRNA (Figure [2A](#F2){ref-type="fig"}, top) and by changes in eIF2 TC levels. Under nonstarvation conditions, where TC levels are high, ribosomes translate the first uORF (uORF1). Following termination at the uORF1 stop codon, the 40S ribosomal subunit resumes scanning. A TC readily binds the scanning 40S subunit enabling reinitiation at one of the subsequent inhibitory uORFs (uORFs2-4), which prevents ribosomes from scanning to the *GCN4* main ORF (mORF) and synthesizing GCN4 protein. Under amino acid starvation conditions, a cellular stress-response process known as general amino acid control is triggered. The protein kinase GCN2 is activated and phosphorylates eIF2α, converting eIF2 from a substrate to an inhibitor of its guanine-nucleotide exchange factor eIF2B. As GTP binding is a prerequisite for Met-tRNA~i~^Met^ binding to eIF2, GCN2 phosphorylation of eIF2 impairs TC formation. The reduction in TC levels, in turn, causes ribosomes, following translation of uORF1, to scan for a longer time and thus longer distance on the *GCN4* mRNA before re-binding a TC and becoming competent to initiate translation. The scanning ribosomes traverse past the inhibitory uORFs2-4 without initiating, and then acquire a TC and initiate translation at the *GCN4* start codon. In the absence of eIF2 phosphorylation, such as in yeast lacking GCN2, mutations that impair TC formation or TC binding to the ribosome can also stimulate *GCN4* expression, conferring a general control derepressed (Gcd^−^) phenotype ([@B26],[@B27]). To quantify the impact of the eIF2γ mutations on *GCN4* expression, a *GCN4-lacZ* reporter was introduced into the *gcn2Δ* strains expressing WT or mutant forms of eIF2γ. While the eIF2γ-V281T mutation slightly elevated *GCN4-lacZ* expression in our previous report ([@B9]), the eIF2γ-V281T mutation did not significantly impact *GCN4-lacZ* expression in this analysis, consistent with WT growth rate of strains expressing this mutant form of eIF2γ. In contrast, the eIF2γ-V281K mutation, which caused a significant slow-growth phenotype, resulted in an ∼8-fold increase in *GCN4-lacZ* expression compared to cells expressing WT eIF2γ (Figure [2A](#F2){ref-type="fig"}) ([@B9]). Cells expressing the eIF2γ-I318L mutant displayed a modest increase in *GCN4-lacZ* expression, while the most substantial *GCN4* derepression was observed for the eIF2γ-I318M mutation with a 16-fold increase in *GCN4-lacZ* expression (Figure [2A](#F2){ref-type="fig"}).

![The eIF2γ-I318M mutation derepresses *GCN4* reporter expression and reduces start codon selection stringency. (**A**) A *GCN4-lacZ* reporter was introduced into yeast strains expressing the indicated wild-type or mutant forms of eIF2γ. (**B**) An *ATF4-luc* and *Renilla* reporter plasmid were transiently co-transfected with the indicated eIF2γ overexpression plasmids into HEK293T cells. (**C**) *his4(UUG)-lacZ* and *HIS4(AUG)-lacZ* reporters were introduced into yeast strains expressing the indicated wild-type or mutant forms of eIF2γ. Means and standard deviations of β-galactosidase (A,C) or relative luciferase (B) activities were calculated from three independent transformants (A,C) or biological replicates (B). Statistically significant differences from WT eIF2γ β-galactosidase activities (A,C) or relative luciferase activities in cells transfected with an empty vector (B) are highlighted by an asterisk (\*) and were calculated using a Student's *t*-test with a *P*-value threshold of *P* = 0.05.](gky1213fig2){#F2}

Expression of *ATF4*, the human homolog of *GCN4*, is also controlled by TC levels through regulated translation reinitiation at uORFs in the *ATF4* mRNA leader. As in the *GCN4* mRNA, the 40S ribosomal subunit readily resumes scanning following translation of uORF1 in the *ATF4* mRNA. The *ATF4* uORF2, which overlaps the 5′ end of the *ATF4* mORF, but in a different reading frame, functionally replaces the inhibitory uORFs2-4 in the *GCN4* mRNA. Under conditions of high TC levels, ribosomes initiate at uORF2 and fail to synthesize ATF4; whereas, when TC levels are lower, ribosomes bypass uORF2 and translate the *ATF4* mORF ([@B28],[@B29]). To quantify the impact of the MEHMO syndrome mutation on *ATF4* expression, HEK293T cells were co-transfected with an *ATF4-luc* reporter and an overexpression vector encoding either WT human eIF2γ or eIF2γ-I259M. Overexpression of WT eIF2γ resulted in *ATF4-luc* expression similar to cells transfected with an empty vector control, while overexpression of eIF2γ-I259M derepressed *ATF4-luc* expression by nearly 2-fold (Figure [2B](#F2){ref-type="fig"}). Taken together, these results suggest that the yeast I318M and human I259M mutations in eIF2γ impair TC formation or TC binding to the scanning ribosome.

In addition to modulating *GCN4* expression, mutations that impair eIF2 function have also been found to reduce the stringency of start codon selection ([@B8]). Mutations that weaken Met- tRNA~i~^Met^ binding to eIF2 are thought to allow premature release of Met- tRNA~i~^Met^ from eIF2 and enable ribosomes to initiate translation at non-AUG codons (a [su]{.ul}ppressor of [i]{.ul}nitiation (Sui^−^) phenotype) ([@B3],[@B5],[@B8]). To determine if the fidelity of start site selection is modulated in the eIF2γ mutants, plasmid-borne *HIS4-lacZ* reporters with either an AUG or UUG start codon were introduced into the yeast strains expressing WT or mutant forms of eIF2γ. As observed previously ([@B30]), cells expressing WT eIF2γ displayed a high level of stringency for start site selection with *HIS4-lacZ* expression from the UUG-initiated reporter at ∼2%, the level obtained from the AUG-initiated reporter (Figure [2C](#F2){ref-type="fig"}). While the UUG/AUG initiation ratio in cells expressing eIF2γ-V281T and eIF2γ-I318L were not significantly different from cells expressing WT eIF2γ, consistent with the mild phenotypes of these mutations in the growth and *GCN4* expression studies, both the V281K and I318M mutations increased the UUG/AUG initiation ratio by ∼2.5-fold (Figure [2C](#F2){ref-type="fig"}). This reduction in the stringency of start codon selection further supports the notion that the eIF2γ-I318M mutation impairs TC integrity, perhaps lowering the fidelity of start site selection by prematurely releasing Met-tRNA~i~^Met^ at non-AUG codons during the ribosome scanning process.

Overexpression of tRNA~i~^Met^ suppresses the slow growth phenotype in yeast expressing eIF2γ-I318M {#SEC3-3}
---------------------------------------------------------------------------------------------------

As our structural analysis indicated that the I259M mutation might disrupt TC integrity by impairing Met-tRNA~i~^Met^ binding to the eIF2 complex, we next tested whether overexpression of tRNA~i~^Met^ could suppress the slow-growth and translation initiation phenotypes observed for the analogous eIF2γ-I318M mutant in yeast. High copy-number plasmids encoding yeast eIF2α (*SUI2*), eIF2β (*SUI3*), tRNA~i~^Met^ (*IMT4*), or an empty vector control were introduced into yeast strains expressing WT eIF2γ, eIF2γ-V281K or eIF2γ-I318M. Cells expressing WT eIF2γ and overexpressing either eIF2α or tRNA~i~^Met^ grew similarly to the vector control, while overexpression of eIF2β resulted in a slight growth defect as previously reported (Figure [3A](#F3){ref-type="fig"}, rows 1--4) ([@B16]). Consistent with the growth defects noted in Figure [1E](#F1){ref-type="fig"}, the empty vector transformants of both the eIF2γ-V281K and eIF2γ-I318M mutants exhibited severe slow-growth phenotypes (Figure [3A](#F3){ref-type="fig"}, rows 5 and 9) ([@B9]). As we reported previously, the eIF2γ-V281K mutation impairs eIF2β binding to eIF2γ ([@B9]). In accord with this eIF2 complex assembly defect, overexpression of eIF2β, but not eIF2α or tRNA~i~^Met^, partially suppressed the slow-growth phenotype of the eIF2γ-V281K mutant (Figure [3A](#F3){ref-type="fig"}, row 7) by restoring eIF2 complex levels ([@B9]). In contrast to the eIF2γ-V281K mutant, overexpression of eIF2β exacerbated the growth defect of the eIF2γ-I318M mutant (Figure [3A](#F3){ref-type="fig"}, row 11). The cause of this enhanced growth defect is unclear. Intriguingly, overexpression of tRNA~i~^Met^ restored the growth of the eIF2γ-I318M mutant to near WT levels (Figure [3A](#F3){ref-type="fig"}, row 12). As western analyses indicated that overexpression of eIF2α, eIF2β or tRNA~i~^Met^ did not affect the levels of the WT or mutant eIF2γ proteins (Figure [3B](#F3){ref-type="fig"}), we propose that overexpression of tRNA~i~^Met^ suppresses the growth defect of the eIF2γ-I318M mutant by restoring eIF2 TC formation.

![Overexpression of tRNA~i~^Met^ suppresses the slow growth phenotype of yeast expressing the eIF2γ-I318M mutant. (**A**) 10-fold serial dilutions of yeast strains expressing the indicated wild-type or mutant forms of eIF2γ and co-transformed with an empty vector or with high copy-number plasmids containing the yeast eIF2α (*SUI2*), eIF2β (*SUI3*) or tRNA~i~^Met^ (*IMT4*) genes were spotted onto SD minimal medium supplemented with required amino acids and incubated at 30°C for 3 days. (**B**) WCEs from yeast strains described in panel (A) were subjected to SDS-PAGE followed by immunoblotting with rabbit polyclonal antisera against yeast eIF2γ, eIF2β, eIF2α or GCD6 (eIF2Bϵ). The asterisk (\*) indicates a non-specific immunoblot band.](gky1213fig3){#F3}

To further explore the role of tRNA~i~^Met^ in modulating eIF2γ-I318M function, *GCN4-lacZ* reporter activity was analyzed in yeast cells expressing WT eIF2γ, eIF2γ-V281K or eIF2γ-I318M with either a vector control or tRNA~i~^Met^ overexpression. In accordance with our earlier observation, both the V281K and I318M mutations in eIF2γ caused robust derepression of *GCN4-lacZ* expression (Figure [4A](#F4){ref-type="fig"}, white bars). Additionally, overexpression of tRNA~i~^Met^ dampened the level of *GCN4* expression by roughly 50% in both the eIF2γ-V281K and eIF2γ-I318M strains (Figure [4A](#F4){ref-type="fig"}, black bars). These data suggest that tRNA~i~^Met^ overexpression is likely sufficient to drive an increase in eIF2 TC formation by mass action in both the eIF2γ-V281K and eIF2γ-I318M mutant cells.

![Overexpression of tRNA~i~^Met^ suppresses the *GCN4* induction, but not translation start codon stringency defect, caused by the eIF2γ-I318M mutation. A *GCN4-lacZ* reporter (**A**) or (**B**) *his4(UUG)-lacZ* and *HIS4(AUG)-lacZ* reporters were introduced into yeast strains expressing the indicated WT or mutant forms of eIF2γ with or without overexpression of tRNA~i~^Met^ (*IMT4*). Means and standard deviations of β-galactosidase activities were calculated for three independent transformants. Statistically significant differences in β-galactosidase activities for strains expressing mutant versus WT eIF2γ with empty vector (\*) or for strains overexpressing tRNA~i~^Met^ versus empty vector (\#) are indicated and were calculated using a Student's *t*-test with a *P*-value threshold of *P* = 0.05.](gky1213fig4){#F4}

We next assessed the impact of tRNA~i~^Met^ overexpression on start codon selection stringency in the yeast strains expressing WT eIF2γ, eIF2γ-V281K or eIF2γ-I318M. As we observed above, both the eIF2γ-V281K and eIF2γ-I318M mutations elevated the UUG/AUG initiation ratio, indicating impaired fidelity of start codon selection (Figure [4B](#F4){ref-type="fig"}, white bars). Interestingly, overexpression of tRNA~i~^Met^ did not attenuate the increase in UUG-*lacZ* expression in either of the eIF2γ mutants (Figure [4B](#F4){ref-type="fig"}, black bars). As will be discussed in more detail below, the translation start site fidelity defect in the eIF2γ-I318M mutant was likely due to premature release of eIF2, but not Met-tRNA~i~^Met^, from the scanning ribosome. Accordingly, overexpression of tRNA~i~^Met^ and the attendant increase in TC levels was not expected to impact start site selection.

The eIF2γ-I318M mutation impairs Met-tRNA~i~^Met^ binding both *in vitro* and *in vivo* {#SEC3-4}
---------------------------------------------------------------------------------------

Based on the location of the I218 residue of the *S. solfataricus* aIF2 (corresponding to residue I318 of yeast eIF2γ) in the aIF2 TC (Figure [1A](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}), the altered *GCN4* mRNA translation in the eIF2γ-I318M mutant cells (Figure [2A](#F2){ref-type="fig"}), and the co-suppression of the cell growth and *GCN4* expression defects in the mutant by overexpression of tRNA~i~^Met^ (Figures [3A](#F3){ref-type="fig"} and [4A](#F4){ref-type="fig"}), we hypothesized that the I318M mutation impaired Met-tRNA~i~^Met^ binding to eIF2. To assess the impact of the eIF2γ-I318M mutation on eIF2 complex integrity and TC formation, we first examined co-precipitation of the eIF2α and eIF2β subunits with His-tagged WT eIF2γ or eIF2γ-I318M. As controls, the assays were also performed using extracts from strains expressing untagged eIF2γ or His-tagged eIF2γ-V281K. Whereas no eIF2 subunits were precipitated with Ni^2+^ affinity resin from the lysates of cells expressing untagged eIF2γ (Figure [5A](#F5){ref-type="fig"}, lane 5), both eIF2α and eIF2β were readily co-precipitated with His-tagged WT eIF2γ (Figure [5A](#F5){ref-type="fig"}, lane 6). The eIF2γ-V281K mutation, as reported previously ([@B9]), impaired eIF2β, but not eIF2α, binding to eIF2γ (Figure [5A](#F5){ref-type="fig"}, lane 8); however, the eIF2γ-I318M mutant pulled-down eIF2α and eIF2β to the same extent as WT eIF2γ (Figure [5A](#F5){ref-type="fig"}, lane 7). Thus, the eIF2γ-I318M mutation did not affect eIF2 complex formation. We next used the same co-precipitation assays to assess TC formation by monitoring the pulldown of Met-tRNA~i~^Met^ with the eIF2 complexes. Total RNA was isolated from the pellets of the pulldown assays and RT-PCR was used to specifically amplify tRNA~i~^Met^ as described in the 'Materials and Methods' section. As shown in the bottom panel of Figure [5A](#F5){ref-type="fig"}, His-tagged eIF2γ-V281K pulled down lower levels of Met-tRNA~i~^Met^ than WT eIF2γ, a downstream consequence of reduced eIF2 heterotrimer formation in the eIF2γ-V281K mutant (Figure [5A](#F5){ref-type="fig"}, lanes 6 and 8). The I318M mutation had a much more profound impact on TC levels with substantially reduced amounts of Met-tRNA~i~^Met^ pulled down with the eIF2γ-I318M mutant (Figure [5A](#F5){ref-type="fig"}, lane 7), indicating a defect in TC formation.

![The eIF2γ-I318M mutation reduces eIF2--GTP--Met-tRNA~i~^Met^ TC formation. (**A**) WCEs from yeast strains expressing the indicated WT or mutant forms of untagged or His-tagged eIF2γ were either immediately processed (Input; lanes 1--4) or incubated with Ni-NTA resin (His-eIF2γ pull-down; lanes 5--8). Input and pull-down protein samples were subjected to SDS-PAGE followed by immunoblotting (western blot, WB) with rabbit polyclonal antisera against yeast eIF2γ, eIF2β and eIF2α. Input and pull-down RNA samples were subjected to RT-PCR using oligonucleotide primers specific to yeast tRNA~i~^Met^, and reaction products were resolved by gel electrophoresis. The asterisk (\*) indicates a non-specific immunoblot band migrating faster than eIF2γ. (**B** and **C**) \[^35^S\]Met-tRNA~i~^Met^ plus non-hydrolyzable GDPNP (B) or \[^3^H\]GDP (C) were incubated with increasing concentrations of purified eIF2 complexes containing WT eIF2γ (black circles) or eIF2γ-I318M (blue squares), followed by vacuum filtration. Each data point represents the mean and error bars indicate the standard deviation for the fraction of \[^35^S\]Met-tRNA~i~^Met^ or \[^3^H\]GDP bound to eIF2 in nitrocellulose filter bindings assays from three independent experiments. (**D**) WCEs from yeast strains expressing the indicated WT or mutant forms of untagged or His-tagged eIF2γ with or without overexpression of tRNA~i~^Met^ were either immediately processed (Input; lanes 1--8) or incubated with Ni-NTA resin (His-eIF2γ pull-down; lanes 9--16). Input and pull-down protein samples were subjected to SDS-PAGE followed by immunoblotting (western blot, WB) with rabbit polyclonal antisera against yeast eIF2γ, eIF2β or eIF2α. Input and pull-down RNA samples were subjected to RT-PCR using oligonucleotide primers specific to yeast tRNA~i~^Met^, and reaction products were resolved by gel electrophoresis.](gky1213fig5){#F5}

To further examine the impact of the eIF2γ-I318M mutation on TC formation, we purified the eIF2 complexes from strains expressing either WT eIF2γ or the eIF2γ-I318M mutant. Yeast tRNA~i~^Met^ was transcribed *in vitro* and aminoacylated with \[^35^S\]Met using purified recombinant *E. coli* methionyl-tRNA synthetase. The \[^35^S\]Met-tRNA~i~^Met^ was then mixed with increasing concentrations of the highly purified eIF2 complexes in the presence of the non-hydrolyzable GTP analog GDPNP. Filter binding assays were used to assess \[^35^S\]Met-tRNA~i~^Met^ binding. The WT eIF2 complexes bound Met-tRNA~i~^Met^ with an observed equilibrium dissociation constant (*K*~d~) of 18 ± 2 nM (Figure [5B](#F5){ref-type="fig"}), which is comparable to the value obtained in previous reports ([@B24],[@B21]). Intriguingly, the purified eIF2 complexes containing eIF2γ-I318M bound Met-tRNA~i~^Met^ with ∼5-fold lower affinity (*K*~d~ = 98 ± 10 nM). As the binding of GTP and Met-tRNA~i~^Met^ to eIF2 are thermodynamically coupled, the apparent Met-tRNA~i~^Met^ binding defect observed for the eIF2 complexes containing eIF2γ-I318M could be due to a defect in guanine nucleotide or in Met-tRNA~i~^Met^ binding. Because eIF2 has a higher affinity for GDP than for GTP ([@B24]), we used filter binding assays to monitor \[^3^H\]GDP binding to eIF2 as a means to examine the impact of the eIF2γ mutation on guanine nucleotide binding. As shown in Figure [5C](#F5){ref-type="fig"}, the eIF2 complexes containing WT eIF2γ (*K*~d~ = 30 ± 6) or eIF2γ-I318M (*K*~d~ = 27 ± 7) bound \[^3^H\]GDP with similar affinities that were comparable to previously reported measurements for WT eIF2 ([@B24],[@B21]). Thus, the Met-tRNA~i~^Met^ binding defect associated with the eIF2γ-I318M mutation is not due to a defect in guanine nucleotide binding. Taken together, the data from the pulldown assays and the *in vitro* binding assays indicate that the eIF2γ-I318M mutation in yeast eIF2, and by analogy the corresponding eIF2γ-I259M mutation identified in the patient with MEHMO syndrome, impairs eIF2 TC integrity through a defect in Met-tRNA~i~^Met^ binding.

Based on the co-suppression of cell growth and *GCN4* expression defects in the eIF2γ-I318M mutant by overexpression of tRNA~i~^Met^ (Figures [3A](#F3){ref-type="fig"} and [4A](#F4){ref-type="fig"}), we hypothesized that tRNA~i~^Met^ overexpression is likely sufficient to drive an increase in eIF2 TC formation by mass action. To assess the impact of tRNA~i~^Met^ overexpression on TC formation, we introduced a high copy-number plasmid encoding yeast tRNA~i~^Met^ or empty vector control into yeast strains expressing WT eIF2γ, eIF2γ-I318M or eIF2γ-V281K and then examined co-precipitation of eIF2α, eIF2β and Met-tRNA~i~^Met^ with His-tagged eIF2γ. Strains expressing untagged eIF2γ were utilized as a negative control, and no eIF2 TC components were precipitated with Ni^2+^ affinity resin from the lysates of cells expressing untagged eIF2γ (Figure [5D](#F5){ref-type="fig"}, lanes 9 and 10). eIF2α, eIF2β and Met-tRNA~i~^Met^ were readily co-precipitated with His-tagged WT eIF2γ independent of tRNA~i~^Met^ overexpression (Figure [5D](#F5){ref-type="fig"}, lanes 11 and 12). As observed previously (Figure [5A](#F5){ref-type="fig"}), reduced levels of eIF2β and Met-tRNA~i~^Met^, but not eIF2α, were co-precipitated with the eIF2γ-V281K mutant (Figure [5D](#F5){ref-type="fig"}, lane 15). Overexpression of tRNA~i~^Met^ slightly elevated Met-tRNA~i~^Met^ binding to eIF2γ-V281K (Figure [5D](#F5){ref-type="fig"}, lanes 15 and 16), consistent with the partial suppression of the *GCN4* expression defects in the eIF2γ-V281K mutant by overexpression of tRNA~i~^Met^ (Figure [4A](#F4){ref-type="fig"}). The eIF2γ-I318M mutant did not affect eIF2 heterotrimer formation, as WT eIF2γ and eIF2γ-I318M pulled down similar amounts of both the eIF2α and eIF2β subunits (Figure [5D](#F5){ref-type="fig"}, lanes 11--14). However, the I318M mutation substantially impaired Met-tRNA~i~^Met^ binding (Figure [5D](#F5){ref-type="fig"}, lane 13), and co-precipitation of Met-tRNA~i~^Met^ with eIF2γ-I318M was restored in cells overexpressing tRNA~i~^Met^ (Figure [5D](#F5){ref-type="fig"}, lanes 13 and 14). Thus, overexpression of tRNA~i~^Met^ is sufficient to drive an increase in eIF2 TC formation by mass action in the eIF2γ-I318M mutant cells.

DISCUSSION {#SEC4}
==========

In this study, we address the molecular defect in eIF2 function caused by the eIF2γ-I259M mutation originally identified in a patient with MEHMO syndrome. Based on the location of the corresponding I318 residue in yeast eIF2γ (Figure [1D](#F1){ref-type="fig"}) and I218 residue in *Ss* aIF2γ (Figure [1C](#F1){ref-type="fig"}), we proposed that the mutation might impact Met-tRNA~i~^Met^ binding to eIF2. Consistent with this hypothesis, substitution of Met for I259 in a human eIF2γ overexpression construct or for I318 in yeast eIF2γ resulted in derepression of *ATF4* or *GCN4* expression, respectively, which are sensitive *in vivo* reporters of eIF2 TC levels. The yeast eIF2γ-I318M mutation also lowered the stringency of start codon selection. Finally, biochemical studies revealed reduced binding of Met-tRNA~i~^Met^ to the mutant eIF2 complexes both in crude yeast extracts and with the purified protein. Taken together these studies reveal that defective Met-tRNA~i~^Met^ binding to eIF2 is a cause of MEHMO syndrome.

To date, four mutations in eIF2γ have been linked to MEHMO syndrome. While severely affected patients exhibit all MEHMO symptoms (Mental deficiency, Epilepsy, Hypogenitalism, Microcephaly and Obesity), less affected patients exhibit only a subset of symptoms. It is interesting to speculate that the impact of the mutations on distinct functions of eIF2γ may play a critical role in determining the phenotype and symptom severity of patients with MEHMO syndrome. Substitution of Thr for I222 on the back side of the GTP-binding domain of eIF2γ impaired eIF2 complex integrity by disrupting binding of the eIF2β subunit to eIF2γ ([@B9]). The corresponding yeast eIF2γ-V281T mutation caused a slight elevation in *GCN4* expression ([@B9]), though not statistically significant in this report (Figure [2A](#F2){ref-type="fig"}), and a modest increase in translation initiation at a near cognate UUG codon ([@B9]). The milder phenotypes in the yeast eIF2γ-V281T versus the eIF2γ-I318M mutant is consistent with the more severe symptoms in the patient with the eIF2γ-I259M mutation. In further support of this correlation between yeast phenotypes and symptoms in patients, an S108R mutation near a Zn^2+^ binding element in eIF2γ resulted in a somewhat milder form of MEHMO syndrome and the corresponding D167R mutation in yeast had no impacts on cell growth or reporter gene expression ([@B12]). The fourth mutation in eIF2γ identified in patients with MEHMO syndrome, eIF2γ-I465Sfs\*4, substitutes three new residues in place of the native eight C-terminal residues in eIF2γ. While a molecular explanation for how this mutation impacts eIF2 function has not been revealed, the corresponding mutation at the C-terminus of yeast eIF2γ mimicked the effects of the V281T mutation. A fifth eIF2γ mutation was identified upon resequencing samples from patients with undefined XLID. A V151L mutation was identified in a patient; however, because of the nature of the study it has not been possible to determine whether the mutation is linked to MEHMO syndrome. Despite this limitation, it is noteworthy that the corresponding V210L mutation in yeast eIF2γ resulted in a 12-fold increase in *GCN4-lacZ* expression and a 4-fold increase in the UUG/AUG initiation ratio ([@B9]). While the impacts of mutations in eIF2 on cell growth and reporter assays in single-celled yeast would not be expected to perfectly correlate with the severity of tissue-specific symptoms in patients with the corresponding mutations, our studies have demonstrated that yeast serves as a good system to model the eIF2γ mutations identified in patients with MEHMO syndrome.

The studies of the eIF2γ-I222T mutant revealed that defects in eIF2 heterotrimer formation could cause MEHMO syndrome ([@B9]). The I222T mutation lies in a cavity that forms the docking site for eIF2β to bind to eIF2γ. Consistent with this location, the mutation impaired eIF2β association with eIF2γ and the growth defect in yeast expressing the corresponding mutation could be suppressed by overexpression of eIF2β ([@B9]), as shown for the related mutation eIF2γ-V281K in Figure [3A](#F3){ref-type="fig"}. The eIF2γ-I318M mutation does not impair eIF2 heterotrimer formation (Figure [5A](#F5){ref-type="fig"}), but instead impairs the binding of Met-tRNA~i~^Met^ to eIF2 (Figure [5](#F5){ref-type="fig"}). Examination of the structures of the isolated archaeal aIF2--GTP--Met-tRNA~i~^Met^ TC (Figure [1A](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}) and the analogous yeast eIF2--GTP--Met-tRNA~i~^Met^ complex bound to the 40S subunit (Figure [1D](#F1){ref-type="fig"}) reveals that the I318 residue in yeast eIF2γ (and by analogy the I259 residue in human eIF2) lies near the methionine-binding site. A cluster of 12 residues forms a shell around the methionine docking site on eIF2γ (Figure [1D](#F1){ref-type="fig"}). Mutational studies in yeast have implicated four of these residues in Met-tRNA~i~^Met^ binding to eIF2. The yeast eIF2γ mutations Y142H and G397A were previously isolated in screens for mutants that derepress *GCN4* expression ([@B4],[@B31]). In addition, both of these mutations reduce the fidelity of translation start site selection causing increased UUG/AUG ratios ([@B4]). Consistent with these genetic phenotypes, the slow-growth phenotype of yeast expressing eIF2γ-G397A was suppressed by overexpression of tRNA~i~^Met^ ([@B32]) and the Y142H mutation in eIF2γ was shown to impair Met-tRNA~i~^Met^ binding to purified eIF2 *in vitro* ([@B33]). As shown in this study, the slow-growth phenotype associated with eIF2γ-I318M mutation was suppressed by overexpression of tRNA~i~^Met^ (Figure [3A](#F3){ref-type="fig"}) and the purified eIF2 complex containing eIF2γ-I318M was defective for binding Met-tRNA~i~^Met^ (Figure [5](#F5){ref-type="fig"}). While the I318 residue is not in the shell of residues that directly form the Met binding pocket in eIF2γ (Figure [1D](#F1){ref-type="fig"}), the adjacent residue R319 (Figure [1D](#F1){ref-type="fig"}) is part of the Met binding pocket and mutation of R319 to Asp is lethal in yeast ([@B32]). We propose that the eIF2γ-R319D mutation impairs Met recognition and that the adjacent eIF2γ-I318M mutation described in this study impairs Met-tRNA~i~^Met^ binding indirectly by impacting the position of R319 and its ability to contribute to Met recognition and binding. As all 12 residues forming the Met binding pocket in eIF2γ are well conserved in evolution, it is tempting to speculate that this conservation is driven by the requirement to initiate translation with Met. While mutations in the Met recognition pocket might enable eIF2 to bind alternate elongator aminoacyl-tRNAs and thereby initiate translation with residues other than Met, which could be of interest in biotechnology, the critical roles played by conserved tRNA~i~^Met^ residues in translation start site selection ([@B34]) indicate that simply relaxing the stringency of Met binding is not likely to enable initiation with alternate aminoacyl-tRNAs.

The defect in Met-tRNA~i~^Met^ binding and the accompanying reduced levels of eIF2 TCs in yeast expressing eIF2γ-I318M readily accounts for the elevated *GCN4* expression. As previously demonstrated ([@B27],[@B16]), regulated translation reinitiation at the uORFs on the *GCN4* mRNA inversely couple GCN4 synthesis to TC levels. Consistent with this idea, overexpression of tRNA~i~^Met^ in the eIF2γ-I318M mutant, which through mass action elevates TC levels (Figure [5D](#F5){ref-type="fig"}), suppresses the induction of *GCN4* expression (Figure [4A](#F4){ref-type="fig"}). In contrast, overexpression of tRNA~i~^Met^ failed to restore start codon selection stringency in the eIF2γ-I318M mutant (Figure [4B](#F4){ref-type="fig"}). This differential effect of overexpression of tRNA~i~^Met^ on *GCN4* expression and start codon selection stringency in the eIF2γ-I318M mutant (Figure [4](#F4){ref-type="fig"}) likely reflects the ordered pathway of translation initiation. As the TC must bind to the 40S subunit prior to mRNA binding and start codon selection, the stringency of start site selection is not expected to be sensitive to TC levels. Thus, restoring TC levels in the eIF2γ-I318M mutant failed to suppress near cognate initiation. However, this raises the question of how defects in TC formation relax the stringency of start codon selection in the eIF2γ-I318M mutant. One possibility is that the lowered affinity of eIF2γ-I318M for Met-tRNA~i~^Met^ results in premature release of eIF2, but not Met-tRNA~i~^Met^, from the scanning ribosome. This might then allow the Met-tRNA~i~^Met^ to move from its initial binding site in the *P*~out~ location that is conducive to ribosome scanning and transient inspection of the mRNA sequence for a start codon to a more fully engaged *P*~in~ location that prevents further scanning and marks selection of the translation start codon (AUG or near cognate) ([@B1]). A second possibility is that the I318M mutation might have a greater impact on Met-tRNA~i~^Met^ binding to eIF2 in the *P*~out~ versus *P*~in~ state. Greater destabilization of the *P*~out~ state would shift the equilibrium to the *P*~in~ state and reduce the stringency of start codon selection. However, these simple models do not account for the critical role of eIF1 in translation start site selection. Genetic, biochemical and structural studies have established that eIF1 acts as a gatekeeper to block P~i~ and subsequently eIF2--GDP release until a codon-anticodon match is established between the mRNA and Met-tRNA~i~^Met^ in the *P* site of the ribosome ([@B1],[@B2],[@B35]). Considering this critical role of eIF1, the eIF2γ mutation might relax start codon selection stringency by either enabling eIF2 release prior to eIF1 release or by prompting premature release of eIF1 in the absence of perfect anticodon--codon complementarity. The latter model was previously invoked to explain the relaxed start codon selection stringency of eIF2γ mutants that do not affect Met-tRNA~i~^Met^ binding affinity ([@B5]). Accordingly, it was proposed that the eIF2γ mutations alter the positioning of Met-tRNA~i~^Met^ in the *P* site to provoke eIF1 release at near cognate start codons ([@B5]). Perhaps the eIF2γ-I318M mutation in addition to weakening Met-tRNA~i~^Met^ binding, alters the conformation of Met-tRNA~i~^Met^ on the scanning ribosome to enable selection of a near cognate start codon and release of eIF1 in the absence of perfect base-pairing complementarity between the mRNA codon and the anticodon of tRNA~i~^Met^.

Finally, it is intriguing to compare the impacts of mutations in eIF2γ with mutations in the guanine nucleotide exchange factor eIF2B ([@B44]). eIF2B plays a critical role in determining eIF2 TC levels by regulating the levels of GTP-bound eIF2 ([@B45]). Following selection of the translation start codon by the scanning PIC, eIF2 completes hydrolysis of the bound GTP and P~i~ is released ([@B2]). Subsequently, eIF2 in complex with GDP is released from the PIC. In order for eIF2 to participate in additional rounds of translation initiation, the GDP bound to eIF2 must be exchanged by GTP in a reaction catalyzed by eIF2B ([@B1]). Mutations have been identified in each of the five subunits of eIF2B that cause leukoencephalopathy with vanishing white matter (VWM) ([@B44],[@B45]). The symptoms associated with MEHMO syndrome and VWM have some overlap, as a subset of patients with MEHMO syndrome also have decreased white matter in their brains ([@B9]). Furthermore, yeast models of VWM and MEHMO syndrome mutations exhibit similar phenotypes with impaired cell growth and increased *GCN4* expression, indicative of decreased eIF2 TC levels (Figures [1E](#F1){ref-type="fig"} and [2A](#F2){ref-type="fig"}) ([@B9],[@B44],[@B46]). However, it is also noteworthy that symptom presentation occurs earlier in the pathogenesis of MEHMO syndrome than VWM disease, and that eIF2γ mutations affect a broad spectrum of tissues that are not impacted by mutations in eIF2B ([@B9],[@B44],[@B46]). While it is unclear why mutations in two essential translation initiation factors result in the different symptoms described for MEHMO syndrome and VWM, one possibility is that impaired translation start site selection, as described here and in our previous analyses of MEHMO syndrome mutations, underlies the additional phenotypes observed in patients with MEHMO syndrome (Figures [2C](#F2){ref-type="fig"} and [4B](#F4){ref-type="fig"}) ([@B9]). Whereas VWM mutations impair eIF2B activity and are proposed to cause disease due to low eIF2 TC levels ([@B46],[@B47]), MEHMO syndrome mutations result in dysregulation of translation initiation through both decreased eIF2 TC levels and reduced start codon selection stringency. How the molecular differences between eIF2γ and eIF2B mutations promote distinct patient phenotypes, and how mutations in eIF2γ, a ubiquitously expressed translation initiation factor, result in the tissue-specific phenotypes associated with MEHMO syndrome will be critical questions to address in future studies.
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